{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:18:21Z","timestamp":1785460701064,"version":"3.56.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.vaccine.2024.126586","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T05:27:51Z","timestamp":1733981271000},"page":"126586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge"],"prefix":"10.1016","volume":"45","author":[{"given":"Stefan","family":"Slamanig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lemus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsoi Ying","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitali","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Abdeljawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Boza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Dolange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benhur","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Gonz\u00e1lez-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schotsaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Palese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weina","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.126586_bb0005","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1093\/cid\/ciab079","article-title":"The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States","volume":"73","author":"Moghadas","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126586_bb0010","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126586_bb0015","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.126586_bb0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.126586_bb0025","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.126586_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103904","article-title":"Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong","volume":"77","author":"Peng","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2024.126586_bb0035","first-page":"13","article-title":"Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine","author":"Patalon","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.126586_bb0040","first-page":"13","article-title":"Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults","author":"Rennert","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.126586_bb0045","first-page":"13","article-title":"Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine","author":"Islam","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.126586_bb0050","first-page":"22","article-title":"SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis","author":"Ssentongo","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126586_bb0055","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.126586_bb0060","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41586-021-04352-y","article-title":"Evolution of enhanced innate immune evasion by SARS-CoV-2","volume":"602","author":"Thorne","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.126586_bb0065","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.126586_bb0070","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2024.126586_bb0075","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41591-022-01699-1","article-title":"Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England","volume":"28","author":"Andrews","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.126586_bb0080","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/14760584.2023.2232851","article-title":"Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early omicron era","volume":"22","author":"Pather","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.126586_bb0085","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMc2113468","article-title":"SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.126586_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(23)00295-5","article-title":"Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial","author":"Lee","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126586_bb0095","author":"WHO"},{"key":"10.1016\/j.vaccine.2024.126586_bb0100","author":"EMA, ECDC"},{"key":"10.1016\/j.vaccine.2024.126586_bb0105","series-title":"Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023 - VRBPAC","author":"FDA'\u2019s Vaccines and Related Biological Products Advisory Committee (VRBPAC)","year":"2023"},{"key":"10.1016\/j.vaccine.2024.126586_bb0110","first-page":"62","article-title":"Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate","author":"Sun","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2024.126586_bb0115","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/vaccines8040771","article-title":"A Newcastle disease virus (NDV) expressing a membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine","volume":"8","author":"Sun","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.126586_bb0120","first-page":"12","article-title":"A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses","author":"Sun","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.126586_bb0125","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.vaccine.2020.12.018","article-title":"Global production capacity of seasonal and pandemic influenza vaccines in 2019","volume":"39","author":"Sparrow","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126586_bb0130","first-page":"12","article-title":"Safety and immunogenicity analysis of a Newcastle disease virus (NDV-HXP-S) expressing the spike protein of SARS-CoV-2 in Sprague Dawley rats","author":"Tcheou","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.126586_bb0135","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01538-22","article-title":"Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice","volume":"10","author":"Gonz\u00e1lez-Dom\u00ednguez","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.vaccine.2024.126586_bb0140","first-page":"12","article-title":"Safety and immunogenicity of a Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate, AVX\/COVID-12-HEXAPRO (patria)","author":"Lara-Puente","year":"2021","journal-title":"Pigs MBio"},{"key":"10.1016\/j.vaccine.2024.126586_bb0145","first-page":"24","article-title":"Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease","author":"Warner","year":"2021","journal-title":"IScience"},{"key":"10.1016\/j.vaccine.2024.126586_bb0150","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41541-024-00870-8","article-title":"Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and omicron challenges","volume":"9","author":"Warner","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2024.126586_bb0155","first-page":"24","article-title":"Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2","author":"Park","year":"2021","journal-title":"IScience"},{"key":"10.1016\/j.vaccine.2024.126586_bb0160","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1016\/j.vaccine.2022.04.078","article-title":"Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomized, placebo-controlled, phase 1\/2 trial in Vietnam","volume":"40","author":"Duc Dang","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126586_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101323","article-title":"Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomised, placebo-controlled, phase 1 trial","volume":"45","author":"Pitisuttithum","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2024.126586_bb0170","first-page":"8","article-title":"Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico","author":"Ponce-de-Le\u00f3n","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2024.126586_bb0175","first-page":"15","article-title":"An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination","author":"Carre\u00f1o","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2024.126586_bb0180","author":"Mathieu"},{"key":"10.1016\/j.vaccine.2024.126586_bb0185","series-title":"Mucosal immune response in BNT162b2 COVID-19 vaccine recipients","author":"Azzi","year":"2022"},{"key":"10.1016\/j.vaccine.2024.126586_bb0190","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add4853","article-title":"Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination","volume":"7","author":"Tang","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2024.126586_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2024.126586_bb0200","first-page":"13","article-title":"SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals","author":"Sano","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.126586_bb0205","first-page":"2","article-title":"A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques","author":"Hassan","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.vaccine.2024.126586_bb0210","first-page":"36","article-title":"A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters","author":"Bricker","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2024.126586_bb0215","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1038\/s41467-021-26178-y","article-title":"ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7","volume":"12","author":"Fischer","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.126586_bb0220","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-023-06809-8","article-title":"Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization","volume":"624","author":"Ye","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.126586_bb0225","series-title":"Comparison of subgenomic and Total RNA in SARS-CoV-2-challenged Rhesus macaques","author":"Dagotto","year":"2021"},{"key":"10.1016\/j.vaccine.2024.126586_bb0230","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1038\/s41467-021-24909-9","article-title":"Neutralizing activity of sputnik V vaccine sera against SARS-CoV-2 variants","volume":"12","author":"Ikegame","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.126586_bb0235","series-title":"Intranasal SARS-CoV-2 omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice","author":"Slamanig","year":"2024"},{"issue":"369","key":"10.1016\/j.vaccine.2024.126586_bb0240","first-page":"1501","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"2020","author":"Hsieh","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.126586_bb0245","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/JS9.0000000000000246","article-title":"The SARS-CoV-2 omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties - an alarming global threat of a surge in COVID-19 cases again?","volume":"109","author":"Chakraborty","year":"2023","journal-title":"Int J Surg"},{"key":"10.1016\/j.vaccine.2024.126586_bb0250","author":"WHO, TAG-CO-VAC"},{"key":"10.1016\/j.vaccine.2024.126586_bb0255","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41423-023-01122-w","article-title":"SARS-CoV-2 immunity in animal models","volume":"21","author":"Chen","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.vaccine.2024.126586_bb0260","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41592-022-01447-w","article-title":"Animal models in SARS-CoV-2 research","volume":"19","author":"Chu","year":"2022","journal-title":"Nat Methods"},{"key":"10.1016\/j.vaccine.2024.126586_bb0265","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.coviro.2021.06.007","article-title":"Animal models of SARS-CoV-2 transmission","volume":"50","author":"de Vries","year":"2021","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2024.126586_bb0270","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41385-018-0006-7","article-title":"Oral cholera vaccination promotes homing of IgA+ memory B cells to the large intestine and the respiratory tract article","volume":"11","author":"Van Splunter","year":"2018","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2024.126586_bb0275","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02280-23","article-title":"Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection","volume":"14","author":"Bhavsar","year":"2023","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2024.126586_bb0280","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.mucimm.2024.01.004","article-title":"Comparison of omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity","volume":"17","author":"Nantel","year":"2024","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2024.126586_bb0285","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1038\/s41467-022-32389-8","article-title":"SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals","volume":"13","author":"Sano","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.126586_bb0290","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/imr.13118","article-title":"Guardians of the oral and nasopharyngeal galaxy: IgA and protection against SARS-CoV-2 infection","volume":"309","author":"Sheikh-Mohamed","year":"2022","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2024.126586_bb0295","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41385-022-00511-0","article-title":"Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection","volume":"15","author":"Sheikh-Mohamed","year":"2022","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2024.126586_bb0300","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S1473-3099(23)00010-5","article-title":"ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5","volume":"23","author":"Yue","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126586_bb0305","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.46234\/ccdcw2021.255","article-title":"GISAID\u2019s role in pandemic response","volume":"3","author":"Khare","year":"2021","journal-title":"China CDC Wkly"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24012684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24012684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T15:12:36Z","timestamp":1739200356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24012684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":61,"alternative-id":["S0264410X24012684"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126586","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126586"}}